Jie He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jie He has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Chunliang Li
Department of Tumor Cell Biology, St. Jude Children’s Research Hospital, Memphis, USA
46 shared publications - Chunyan Zong
Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
46 shared publications - Fengqin Fang
Tongren Hospital, Shanghai, China
46 shared publications - Guopei Zheng
Department of Ophthalmology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
46 shared publications - Jianfeng Shen
Department of Ophthalmology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
46 shared publications - Lingjie Li
Department of Histoembryology, Genetics and Developmental Biology, Shanghai Key Laboratory of Reproductive Medicine, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
46 shared publications
Latest Publications
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from PIKfyve Inhibition Induces Antitumor Immunogenicity by Attenuating STING Trafficking and Lysosomal Degradation
Supplementary Table 4 from PIKfyve Inhibition Induces Antitumor Immunogenicity by Attenuating STING Trafficking and Lysosomal Degradation
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from PIKfyve Inhibition Induces Antitumor Immunogenicity by Attenuating STING Trafficking and Lysosomal Degradation
Supplementary Table 4 from PIKfyve Inhibition Induces Antitumor Immunogenicity by Attenuating STING Trafficking and Lysosomal Degradation
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from PIKfyve Inhibition Induces Antitumor Immunogenicity by Attenuating STING Trafficking and Lysosomal Degradation
ShRNA and sgRNA target sequences
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from PIKfyve Inhibition Induces Antitumor Immunogenicity by Attenuating STING Trafficking and Lysosomal Degradation
ShRNA and sgRNA target sequences
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from PIKfyve Inhibition Induces Antitumor Immunogenicity by Attenuating STING Trafficking and Lysosomal Degradation
Supplementary Table 3 from PIKfyve Inhibition Induces Antitumor Immunogenicity by Attenuating STING Trafficking and Lysosomal Degradation
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from PIKfyve Inhibition Induces Antitumor Immunogenicity by Attenuating STING Trafficking and Lysosomal Degradation
Supplementary Table 3 from PIKfyve Inhibition Induces Antitumor Immunogenicity by Attenuating STING Trafficking and Lysosomal Degradation
- Open Access
- 19 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from PIKfyve Inhibition Induces Antitumor Immunogenicity by Attenuating STING Trafficking and Lysosomal Degradation
ShRNA and sgRNA target sequences
- 19 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from PIKfyve Inhibition Induces Antitumor Immunogenicity by Attenuating STING Trafficking and Lysosomal Degradation
ShRNA and sgRNA target sequences